For Some Lung Cancer Patients Receiving SBRT, One and Done Approach Works Best
BUFFALO, N.Y. — Stereotactic body radiation therapy (SBRT) is a specialized and highly targeted method of delivering radiotherapy, or radiation therapy, to treat cancer. This approach, used to treat many solid-tumor cancers, including lung, liver and kidney cancers, can mean greater convenience and quality of life for patients because it involves fewer individual treatments and can help to spare healthy tissue. A new study led by Anurag Singh, MD, of Roswell Park Comprehensive Cancer Center and presented at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting suggests that a single high-intensity SBRT dose can be as effective as three slightly lower doses of radiation.
Working with colleagues from Roswell Park as well as collaborators from the Cleveland Clinic and Upstate New York Medical University, Dr. Singh undertook a phase II clinical study involving nearly 100 patients treated for early-stage non-small-cell lung cancer (NSCLC) between 2008 and 2015. The patients were randomly assigned to be treated through one of two established stereotactic radiation regimens: either a single dose of 30 grays (Gy) of radiation or 60 Gy delivered through three 20-Gy doses.
They found that the one-dose regimen — which cut patients’ total radiation exposure in half — was at least as effective as the three-dose schedule. Overall and progression-free survival improved modestly for patients treated with a single 30-Gy dose. Additionally, fewer patients treated with a single dose of radiation experienced significant (grade 3-5) side effects.
“Our goal is always to right-size treatment, and we’re especially excited any time we can show that less treatment can be at least as effective as a more intense regimen, maybe even more so,” says Dr. Singh, Professor of Oncology and Director of Radiation Research in the Department of Radiation Medicine at Roswell Park. “Our findings were surprising, because we previously thought that you would sacrifice some measure of efficacy by reducing radiation exposure to this extent. So we were thrilled that that is not the case.”
“There are a lot of important implications here, in terms of patient convenience and quality of life — especially for those who don’t live close to a cancer center — and the ability to combine radiation therapy with immunotherapy or surgery,” adds Dr. Singh, who is currently leading or planning similar studies in other cancer disease sites.
This research was first presented by Dr. Gregory Videtic of the Cleveland Clinic in a Sept. 25 talk at the ASTRO 2016 Annual Meeting in Boston. It will also be presented at the 2016 Best of ASTRO meeting Nov. 11–12 in Fort Lauderdale, Florida, which highlights the most relevant and influential abstracts from the 2016 Annual Meeting, and at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer Dec. 4–7 in Vienna, Austria.
Dr. Singh is grateful for a grant in support of this work from the Roswell Park Alliance Foundation.
The mission of Roswell Park Comprehensive Cancer Center is to understand, prevent and cure cancer. Founded in 1898, Roswell Park is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-800-ROSWELL (1-800-767-9355) or email AskRoswell@Roswellpark.org. Follow Roswell Park on Facebook and Twitter.
Annie Deck-Miller, Senior Media Relations Manager